Worsening anemia signals poorer outcomes in men treated for advanced prostate cancer

May 23, 2006

PORTLAND, Ore. -- Researchers from the Oregon Health & Science University Cancer Institute and Southwest Oncology Group have identified a new method of determining how men with advanced prostate cancer will respond to treatment. They found that worsening anemia during the first three months of hormonal therapy for prostate cancer that has spread predicts shorter survival and earlier relapse.

"These results suggest that by monitoring anemia during the first three months of treatment, we can provide men with a better idea of how well they will fare," said principal investigator Tomasz Beer, M.D., director of the prostate cancer research program in the OHSU Cancer Institute. Beer will present results of this study at the 101st Annual Meeting of the American Urological Association in Atlanta on Tues., May 23.

Researchers also found that race alone was not a strong predictor of survival or disease progression. However, they found that men with the same hemoglobin levels before treatment experienced significantly different overall and progression-free survival depending on whether they were black or white. Hemoglobin levels in the blood are measured to monitor anemia. Lower levels of hemoglobin are considered anemic.

"Outcomes for prostate cancer have always been worse for black men than their white counterparts and the reasons behind this have not been fully understood," Beer said. "Differences in anemia could help us understand why blacks do worse and maybe make it possible to do something about it."

Overall, researchers found that anemic blacks fare worse than anemic whites and that blacks with high baseline hemoglobin fare better than whites with similar hemoglobin levels.

"Our study was not designed to answer questions about this complex and novel finding, but we are examining a number of hypotheses," Beer said.

Anemia is common among newly diagnosed prostate cancer patients with metastatic disease. Approximately one-fourth of these men are anemic. Previous studies have shown that men who are anemic prior to treatment experience shorter survival and are prone to early relapse. One recent study has shown that a decrease in hemoglobin after one month of treatment is predictive of early relapse in men with high-risk prostate cancer that has not spread.

"Relatively little was known about hemoglobin change after the beginning of hormonal therapy for advanced prostate cancer," Beer said. "We were interested in learning how changes in anemia during early treatment impact survival for these men because there are ways of treating anemia. There may be opportunities to study whether treating anemia would improve survival, making it a modifiable risk factor."

Androgen deprivation, or hormonal therapy, is the standard treatment for prostate cancer that has spread beyond the gland. It blocks the production of male hormones that can promote prostate cancer growth. This common treatment for advanced prostate cancer wipes out most male hormones found in the body. It also is known to reduce red cell production, making anemia one of its adverse effects.

"We believed that different men would respond to hormonal therapy differently and that these different responses in hemoglobin could be an independent prognostic factor for men with advanced prostate cancer," Beer said. "We also believed that the effect of anemia on outcomes may vary by race."

Beer and his colleagues tested this hypothesis in a retrospective analysis of SWOG 8894, a randomized study of orchiectomy versus orchiectomy plus flutamide in previously untreated metastatic prostate cancer.

Of the 1,286 subjects enrolled in SWOG 8894, data from 817 subjects were available for this analysis, which included a number of other traditional risk factors beyond hemoglobin, including performance status, Gleason score and disease extent.

The median pretreatment hemoglobin was 13.7 g/dL before treatment and 12.8 g/dL after treatment. Overall, the mean change in hemoglobin between the baseline measurement and 3-month follow-up was a decrease of 0.54 g/dL.

"We now know that baseline hemoglobin and 3-month hemoglobin change are prognostic, even after taking into account these other risk factors," Beer said. "Further study is needed to fully understand the underlying biology of this affect and to determine if reversing anemia can improve survival in patients with advanced prostate cancer."
Particulars: AUA Annual Meeting Abstract No. 1197, "Prognostic Value of Hemoglobin Change After Initiation of Androgen Deprivation Therapy for Newly Diagnosed Metastatic Prostate Cancer: A Multivariate Analysis of SWOG 8894."

This study was funded by the National Cancer Institute.

Visit www.ohsu.edu/news to view all OHSU news releases.

Oregon Health & Science University

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.